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                                        Ovarian cancer is often a lethal disease, and stage at diagnosis 
remains one of the strongest prognostic factors. The high cure rate 
associated with local-stage disease has motivated diverse efforts to 
advance early detection (  1  ,  2  ). This growing interest in early detec-
tion has paralleled the development of high-dimensional molec-
ular technologies for biomarker discovery (  3  ,  4  ); these technologies 
have been used to identify several biomarkers for ovarian cancer. 
Except for a few studies (  5    –    8  ) in which CA125 has been measured 
before diagnosis, to our knowledge, no systematic evaluation of 
prediagnostic marker levels for ovarian cancer has been conducted. 
Candidate markers have typically been characterized in cross-
sectional studies of samples collected at the time of diagnosis 
when contrasts in marker concentrations between women with 
and without cancer are expected to be greatest. Biomarkers of risk 
or early detection, however, must be able to identify women with 
no or few nonspecific symptoms but who are destined to have a 
future clinical diagnosis from women with similar characteristics 
who will remain disease free for the foreseeable future. The length 
of the interval during which this distinction can be made remains 
unknown. 
  Assessment of a biomarker’s potential for early detection or risk 
assessment requires measurements in specimens that were collected 
before diagnosis, typically available only from specimen reposi-
tories of large prospective cohort studies (  9  ). In this article, we 
describe the longitudinal behavior and classiﬁ  cation performance of 
six markers  —  CA125, human epididymis protein 4 (HE4), mesothe-
lin, B7-H4, decoy receptor 3 (DcR3), and spondin-2  —  in prediag-
nostic serum samples from 34 women who were later diagnosed 
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     Background     CA125, human epididymis protein 4 (HE4), mesothelin, B7-H4, decoy receptor 3 (DcR3), and spondin-2 
have been identified as potential ovarian cancer biomarkers. Except for CA125, their behavior in the pre-
diagnostic period has not been evaluated.   
     Methods     Immunoassays were used to determine concentrations of CA125, HE4, mesothelin, B7-H4, DcR3, and 
spondin-2 proteins in prediagnostic serum specimens (1  –  11 samples per participant) that were contributed 
0  –  18 years before ovarian cancer diagnosis from 34 patients with ovarian cancer (15 with advanced-stage 
serous carcinoma) and during a comparable time interval before the reference date from 70 matched con-
trol subjects who were participating in the Carotene and Retinol Efficacy Trial. Lowess curves were fit to 
biomarker levels in cancer patients and control subjects separately to summarize mean levels over time. 
Receiver operating characteristic curves were plotted, and area-under-the curve (AUC) statistics were com-
puted to summarize the discrimination ability of these biomarkers by time before diagnosis.   
     Results     Smoothed mean concentrations of CA125, HE4, and mesothelin (but not of B7-H4, DcR3, and spondin-2) 
began to increase (visually) in cancer patients relative to control subjects approximately 3 years before 
diagnosis but reached       detectable elevations only within the final year before diagnosis. In descriptive 
receiver operating characteristic analyses, the discriminatory power of these biomarkers was limited 
(AUC statistics range = 0.56  –  0.75) but showed increasing accuracy with time approaching diagnosis 
(eg, AUC statistics for CA125 were 0.57, 0.68, and 0.74 for   ≥  4, 2  –  4, and <2 years before diagnosis, 
respectively).   
     Conclusion     Serum concentrations of CA125, HE4, and mesothelin may provide evidence of ovarian cancer 3 years 
before clinical diagnosis, but the likely lead time associated with these markers appears to be less than 
1 year.   
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with ovarian, fallopian tube, or primary peritoneal cancer and from 
70 matched control subjects. These women were participants in the 
Carotene and Retinol Efﬁ  cacy Trial (CARET), a National Cancer 
Institute  –  sponsored randomized, double-blind, placebo-controlled 
chemoprevention trial testing the effects of beta-carotene and 
retinol on the incidence of lung cancer among individuals at high 
risk for lung cancer (  10  ). The behavior of these markers in the 
preclinical period is assessed by describing their discriminatory 
performance of the biomarkers when used individually or in com-
bination and when used in both cross-sectional and longitudinal 
algorithms (  11  ,  12  ). 
  CA125, the current benchmark biomarker for ovarian cancer 
detection, is a high-molecular-weight mucin-type glycoprotein 
that is aberrantly expressed by ovarian cancer and other cancers, 
such as breast cancer (  13  ,  14  ), mesothelioma (  15  ), non-Hodgkin 
lymphoma (  16    –    19  ), leukemia (  20  ), gastric cancer (  21  ), and leio-
myoma and leiomyosarcoma of gastrointestinal origin (  22  ). CA125 
levels have also been found to be elevated in benign conditions, 
such as cirrhosis, benign gynecological conditions, pregnancy, 
ovulation, liver diseases, and congestive heart failure. The role of 
CA125 in health and in disease remains poorly understood. The 
unusual features of the oligosaccharides such as the expression of 
branched-core 1 antennae in       the core type 2   O  -glycans, as well as 
robust   N  -glycosylation, primarily in high mannose and bisecting 
type N-linked glycans linked to CA125, suggest a role for CA125 
in cell-mediated immune response (  23  ). Belisle et al. (  24  ) suggested 
that CA125 could play a role in altering the phenotype of natural 
killer cells, perhaps by binding directly to these or other immune 
cells [for a more comprehensive review, see Scholler and Urban 
(  25  )]. Although the level of CA125 has been shown to be a useful 
marker for monitoring treatment response and disease recurrence 
(  26  ,  27  ), CA125 has not been approved for early detection. Elevated 
CA125 concentrations in serum have been documented 5 years or 
more before diagnosis of ovarian cancer (  5    –    8  ). Studies examining 
the discriminatory performance at the time of diagnosis have 
found that a single threshold rule provides reasonable sensitivity 
and speciﬁ  city overall, with more limited sensitivity for early-stage 
disease (  28  ,  29  ). The reported accuracy for CA125 is not sufﬁ  cient, 
however, to use in population-based screening. 
  We evaluated ﬁ  ve other markers, selected on the basis of their 
classiﬁ  cation performance in cross-sectional studies in a common 
set of specimens from women with ovarian cancer and control 
women with no evidence of cancer (  30  ). The   WFDC2   gene that 
encodes HE4, a member of the family of stable 4-disulﬁ  de core 
proteins, is overexpressed in ovarian tumors, especially in serous 
and endometrioid carcinomas (  31  ,  32  ), lung adenocarcinoma (  33  ), 
and normal endometrial glands and endometrial cancer (  32  ,  33  ), but 
its function has not been determined. Elevated HE4 protein levels 
have been found in serum from patients with ovarian cancer 
(  31  ,  34  ). Mesothelin is a cell surface molecule that binds CA125 and 
may contribute to the metastasis through cell adhesion mechanisms 
(  35    –    37  ). Mesothelin is displayed at the cell surface via a glyco-
sylphosphatidylinositol anchor (  38  ). Proteins with a glycosylphos-
phatidylinositol anchor are structurally and functionally diverse 
and play vital roles in many biological processes (  39  ). The physio-
logical role of mesothelin is not currently understood, and the lack 
of a phenotype change in mesothelin knockout mice led Bera and 
    CONTEXT AND CAVEATS       
    Prior knowledge 
  CA125, human epididymis protein 4, mesothelin, B7-H4, decoy re-
ceptor 3, and spondin-2 have been identified as potential ovarian 
cancer biomarkers.   
    Study design 
  Analysis of prediagnostic serum samples and patient data from the 
Carotene and Retinol Efficacy Trial, a randomized, double-blind, 
placebo-controlled chemoprevention trial testing the effects of be-
ta-carotene and retinol on lung cancer incidence among individ-
uals at high risk for lung cancer. Serum was contributed 0  –  18 years 
before ovarian cancer diagnosis from 34 patients with ovarian can-
cer and 70 matched control subjects. Changes in the levels of these 
biomarkers by time before diagnosis were analyzed.   
    Contribution 
  Concentrations of CA125, human epididymis protein 4, and meso-
thelin (but not of B7-H4, decoy receptor 3, and spondin-2) began to 
increase slightly in cancer patients relative to control subjects ap-
proximately 3 years before diagnosis but became substantially el-
evated only about a year before diagnosis. The discriminatory 
power of these biomarkers was limited, and accuracy only increased  
shortly before diagnosis.   
    Implications 
  The likely lead time associated with these markers was short (<1 
year).   
    Limitations 
  The sample size was small. All women had a history of heavy 
smoking and so results may not apply to other groups. Blood was 
collected at different times across all women, and few samples 
were collected during the last 2  –  3 years before diagnosis. 
    From the Editors       
    
Pastan (  40  ) to conclude that mesothelin is a nonessential protein. 
Soluble forms of mesothelin have been found in serum from cancer 
patients (  41  ), and use of information on both mesothelin and 
CA125 levels may improve diagnostic accuracy over either marker 
alone (  42  ). We also evaluated three other markers that may have 
diagnostic potential: B7-H4, a newly described member of the B7 
family of proteins that is expressed on tumor-associated macro-
phages and appears to be a negative regulator of T-cell response 
(  43  ); spondin-2, a protein of unknown function that may be associ-
ated with the extracellular membrane; and DcR3, a soluble decoy 
receptor member of the tumor necrosis factor receptor family that 
blocks FasL-induced cell death (  44  ). Each of these markers has 
been shown to be elevated in patients with ovarian cancer (  45  ). 
    Participants and Methods 
    Study Population, Blood Collection, and Cancer 
Ascertainment 
  Between January 1, 1983, and December 31, 1994, 18    314 partic-
ipants, including 6289 postmenopausal women between the ages 
of 50 and 69 years, were recruited into CARET at six study cen-
ters, primarily by use of mass mailings to individuals on insurance 
lists. For women, only current or former smokers with at least 20 28   Articles | JNCI  Vol. 102, Issue 1  |  January 6, 2010
pack-years of exposure were eligible. Height and weight were 
measured at a baseline study center visit. Other risk factor infor-
mation was provided at baseline by self-report. Study participants 
were queried routinely (at least annually) through 2005 for new 
health events. Blood specimens were collected according to stan-
dardized procedures every year from the 490 women in the pilot 
phase and every 2 years from the 5799 full-scale trial participants 
through 1996. Briefly, blood was collected in foil-covered vacu-
tainers, centrifuged to separate serum, separated into aliquots in 
2- and 0.5-mL amber vials, and stored locally at     25°C for a 
maximum of 2 weeks before being placed in long-term centralized 
storage at     70°C. 
  Until 2003, all self-reports of cancers were documented with 
pathology reports and centrally reviewed. Subsequently, cancer 
ascertainment was limited to self-report. The agreement rate 
between self-report and central review was 80%. All women pro-
vided written informed consent to participate in CARET. Details 
of the study design for CARET have been published (  10  ). 
  We identiﬁ  ed 35 CARET participants who reported receiving 
a diagnosis of ovarian, fallopian tube, or primary peritoneal cancer 
and who had stored serum specimens available. Each cancer 
patient was matched to two disease-free participants on the basis of 
age, date and study center of enrollment, race or ethnicity, and 
serum specimen availability. In selecting control subjects, the win-
dow allowed for matching on date resulted in a few control sub-
jects whose blood was drawn after the reference date (ie, the date 
of diagnosis for the matched cancer patient). Medical records of 
the 35 cancer patients were centrally reviewed by one of us (G. 
Goodman) for detailed tumor characteristics. One reported cancer 
was found to be a leiomyosarcoma of the fallopian tube and that 
patient was excluded. The corresponding matched control subjects 
for the excluded cancer patient were retained in this analysis. Six 
cancers were identiﬁ  ed only by self-report because neither pa-
thology nor surgery reports were available. This study was ap-
proved by the internal review board of the Fred Hutchinson 
Cancer Research Center.   
    Additional Blood Processing and Quality Assurance 
  Specimen vials were identified by a unique specimen identification 
number and provided by the CARET staff without thawing. All 
specimens for this study were thawed, separated into additional 
aliquots, and refrozen until assayed. To reduce potential bias asso-
ciated with plate-to-plate and positional variation in the bead-
based assays for CA125, HE4, and mesothelin, CARET staff 
defined plate positions for each specimen, assuring that all speci-
mens from matched case  –  control sets were on the same plate in 
random order. Four replicates of a pooled serum sample were 
measured on each plate for quality control. Laboratory staff were 
blinded to all participant-level information throughout the study.   
    Determination of Marker Concentrations in Serum 
Samples 
  Concentrations of CA125, HE4, mesothelin, B7-H4, DcR3, and 
spondin-2 were determined by use of immunoassays. Anti-CA125 
mouse monoclonal antibodies, X306 and X52, were purchased 
from Research Diagnostics, Inc (Flanders, NJ). Anti      -HE4 poly-
clonal antibodies were developed as described previously (  32  ) and 
were kindly provided by Dr Ronny Drapkin       (Dana-Farber Cancer 
Institute). Briefly, HE4-specific polyclonal antibodies were raised 
by immunizing rabbits with a fusion protein composed of the 
mature form of HE4 (amino acids 31  –  125) and glutathione 
  S  -transferase (GST). Affinity-purified antibodies were generated 
by absorption of the crude antiserum to a GST affinity column 
(Pierce Biotechnology, Inc, Rockford, IL) to remove all the GST 
antibodies. The GST antibody  –  depleted serum was then affinity-
purified by passing it over a GST-HE4 column generated by use 
of an AminoLink Coupling Gel column (Pierce Biotechnology, 
Inc). Anti-mesothelin goat polyclonal antibodies were purchased 
from R&D Systems (Minneapolis, MN). Recombinant antibodies 
(single-chain variable fragment) secreted by yeast with a biotin 
attached to a biotin-accepting site fused to the carboxyl-terminal 
end of the binding site after an IgA linker [referred to hereafter as 
biobodies (  46  )] were used in HE4 (  46  ) and mesothelin (  47  ) assays. 
Biobodies have a six-histidine (HIS  6  ) tag in the carboxyl terminus 
of the binding site that permits their purification from yeast cul-
ture supernatants with HIS-Select-Nickel Affinity Gel (Sigma-
Aldrich, St Louis, MO) via the biobody’s HIS  6   tag, pelleting the 
gel  –  biobody complexes, washing away other supernatant compo-
nents, then eluting the biobodies from the gel by competition with 
imidazole buffer (0.3 M imidazole; 0.3 M NaCl; 0.05 M NaP, pH 
8) (Fisher Scientific, Pittsburgh, PA). Centrifugal concentrators 
with a molecular weight cutoff of 30    000 kDa (VWR, West 
Chester, PA) were used to concentrate biobodies from a volume of 
2 mL to 0.5 mL and exchange imidazole buffer with 1X phosphate-
buffered saline (PBS; Fisher Scientific). 
  Serum levels of CA125, HE4, and mesothelin were measured 
by use of bead-based enzyme-linked immunosorbent assays 
(ELISAs) as described previously (  48  ). Brieﬂ  y, all incubations 
were performed at room temperature in the dark. Capture     anti-
bodies against CA125 (X306 monoclonal antibodies at 5   µ  g/mL), 
against HE4 (anti-HE4 polyclonal antibodies at 40   µ  g/mL), or 
against mesothelin (anti-mesothelin polyclonal antibodies at 50 
  µ  g/mL) were covalently coupled to carboxylated polystyrene 
beads (Bio-Rad Laboratories, Inc, Hercules, CA) by activating 
the beads with the ﬁ  rst bead activation buffer (0.1 M sodium 
phosphate, pH 6.2; Sigma, St Louis, MO) containing 1-ethyl-3-
(3-dimethylaminopropyl) carbodiimide hydro  chloride (Pierce, 
Rockford, IL) and   N  -hydroxysulfosuccinimide (Pierce) diluted, 
respectively, to 38 mg/mL and 109 mg/mL in activation buffer    . 
The     coupling buffer was made with 0.05 M 2-(  N  -morpholino)
ethanesulfonic acid, pH 5.0 (Sigma-Aldrich). Washes were per-
formed with PBS supplemented with 0.05% Tween 20; assays, 
blocking of nonspeciﬁ  c sites on beads, and storage were per-
formed in PBS containing 1% bovine serum albumin (Sigma-
Aldrich). The capture antibody was then added to the reaction 
mixture to allow the amines in the protein to react with the acti-
vated intermediate to form an amide bond, through which the 
antibody was attached to the bead. 
  For CA125 assays, X306-coupled beads were incubated with 
serum diluted 1:4 in Bio-Rad Human Serum Diluent for 30 
minutes in 96-well Multiscreen HTS, GV plates (Millipore, 
Billerica, MA). Captured antigen was detected by incubation with 
25   µ  L of biotinylated X52 monoclonal antibody diluted to 2   µ  L/
mL in Bio-Rad Cytokine Detection Antibody Diluent 1:100 for 30 jnci.oxfordjournals.org    JNCI | Articles 29
minutes, followed by incubation with 50   µ  L of phycoerythrin-
conjugated streptavidin (Bio-Rad) diluted 1:100 in Bio-Rad Assay 
Buffer for 10 minutes. Serum was diluted 1:10 for HE4 assays and 
1:5 for mesothelin assays in PBS containing 1% bovine serum 
albumin (Sigma), and 50   µ  L of diluted serum was added to anti-
HE4  –  coupled beads or to anti-mesothelin  –  coupled beads in 
96-well Multiscreen HTS, GV plates and incubated for 30 mi-
nutes. Captured antigen was detected with 25   µ  L of the respective 
biobodies against HE4 at 5   µ  g/  µ  L and against mesothelin at 1   µ  g/
mL that had been preincubated with PhycoLink Streptavidin-
R-Phycoerythrins PJ31S (Prozyme, San Leandro, CA) in PBS 
containing 1% bovine serum albumin for 30 minutes. All plates 
were analyzed with the Bio-Plex Array Reader (Bio-Rad). 
  For B7-H4, DcR3, and spondin-2 immunoassays, generation of 
monoclonal antibodies and ELISA protocols have been published 
(  45  ). Brieﬂ  y, all monoclonal antibodies used in this study were 
generated by immunizing BALB/c mice with the corresponding 
recombinant human protein (B7-H4, DcR3, or spondin-2) that 
had been expressed in either a baculovirus or mammalian expres-
sion system (diaDexus, Inc, South San Francisco, CA). For each 
antigen (B7-H4, DcR3, or spondin-2), a pair of mouse monoclonal 
antibodies, each binding to different epitopes on the antigen, were 
used as capture or detection antibodies in the ELISA. For each 
ELISA, 20  –  25   µ  L of undiluted serum was added to high-binding 
polystyrene plates (Corning Life Sciences, Bedford, MA) that had 
been coated overnight at 4°C with the corresponding capture 
monoclonal antibody at a concentration of 5   µ  g/mL in 1X Tris-
buffered saline. Immobilized antigen was then detected by incuba-
tion with a biotinylated secondary monoclonal antibody at a 
concentration of 3   µ  g/mL in assay buffer (Tris-buffered saline, 1% 
bovine serum albumin, 1% mouse serum, 1% calf serum, and 0.1% 
Tween-20) for 1 hour at room temperature, followed by incuba-
tion with horseradish peroxidase  –  conjugated streptavidin or alka-
line phosphatase  –  conjugated streptavidin diluted 1:10    000 in assay 
buffer for 30 minutes at room temperature. For quantiﬁ  cation of 
antigens in the serum samples, standards of recombinant protein 
and serum from two control subjects were added to each plate and 
tested together with the samples.   
    Statistical Methods 
  Associations between baseline characteristics and ovarian cancer 
status were evaluated by use of   t   tests for continuous variables 
or       2   tests for categorical variables. Percentages may not add 
to 100% because of missing values. Baseline blood values refer to 
the blood specimen obtained at enrollment or first blood draw 
thereafter. 
  To further control for potential plate-to-plate variability in the 
bead-based assays, CA125, HE4, and mesothelin concentrations 
were normalized by dividing each value by the mean of the four 
replicates of pooled serum on the corresponding plate. All six 
marker levels were log-transformed and rescaled by subtracting 
the mean of baseline values in the control group and dividing the 
result by the SD of the baseline control group values. The rescaled 
levels, referred to as “standardized” levels and reported without 
units, allowed direct comparison of results across markers. 
  Descriptive statistics of baseline marker levels were calculated 
for cancer patients and control subjects separately. The mean and 
SD of baseline values in the control group may have deviated 
slightly from 0 and 1, respectively, because of rounding error. For 
visual displays, standardized biomarker levels are presented by 
time before diagnosis for the cancer patients and by time before 
the corresponding reference date (ie, the date of diagnosis for the 
matched cancer patient) for control subjects. To summarize trends 
over time, lowess curves (  49  ) were ﬁ  t to biomarker levels in cancer 
patients and control subjects separately by time before diagnosis or 
reference date. Correlations among biomarkers were assessed on 
standardized baseline values within cancer patients and control 
subjects separately by use of Pearson correlation coefﬁ  cients. 
  Receiver operating characteristic (ROC) curves were plotted, 
and area-under-the curve (AUC) statistics were computed to sum-
marize the discrimination ability of these markers (  50  ). All avail-
able marker levels from cancer patients were divided into the 
following three periods: less than 2 years, 2  –  4 years, and 4 years or 
more before diagnosis. The intervals were selected to allow closer 
examination of the time approaching diagnosis while assuring a 
reasonable number of cancer diagnoses. For control subjects, all 
available marker levels from all time periods were used because 
time before reference date has no particular relevance to their 
distribution. Multiple values per individual were included to 
increase the precision of the estimates of sensitivity and speciﬁ  city. 
Traditional estimates of variability are not accurate in this setting 
and so these curves should be viewed as descriptive only. In explor-
atory analyses, composite markers that were based on the sum or 
the maximum of marker levels for each woman at each time point 
were similarly assessed. 
  Multivariable Cox regression models (  51  ) were used to evaluate 
the risk of ovarian cancer associated with these serum markers and 
to assess their relative contribution to estimated risk after control-
ling for age, family history of breast and ovarian cancer, and, where 
feasible, self-reported race. Education was not included because it 
was not strongly associated with the ovarian cancer risk in this 
study population, and its use caused participants to be excluded for 
missing data. Each biomarker and each composite marker were 
modeled individually as a time-varying covariate to reﬂ  ect changing 
levels over time, similar to what would be observed in a clinical 
setting. For cancer patients, the time to ovarian cancer diagnosis 
was calculated from the date of baseline blood collection. For con-
trol subjects, censoring occurred at the earlier of death from other 
causes or date of last follow-up. To examine the potential value of 
multiple markers for risk prediction, we used forward selection 
methods to obtain a ﬁ  nal risk model. 
  Analyses       were performed with SAS version 9.1 (SAS Institute, 
Cary, NC) with graphical displays generated in R version 2.7.2. All 
statistical tests are two-sided, and   P   values of less than .05 were con-
sidered to be statistically signiﬁ  cant. Using a Bonferroni correction 
to account for testing six markers would imply that only   P   values of 
less than .008 would be considered statistically signiﬁ  cant.     
    Results 
  Cancer patients and matched control subjects from CARET were 
all postmenopausal women who were current or former smokers 
and who had a mean age of 59 years (SD = 5.7 years). All were 
white, except for one matched case  –  control pair of African 30   Articles | JNCI  Vol. 102, Issue 1  |  January 6, 2010
American women. The available information indicated that this 
population was at average risk for ovarian cancer. The distributions 
of most risk factors are generally comparable between cancer 
patients and control subjects (  Table 1  ). Mean standardized base-
line serum levels of all six markers were slightly higher in cancer 
patients than in control subjects, but the only marker with a differ-
ence that approached statistical significance was spondin-2. The 
mean (±SD) CA125 level at baseline was 16.7 U/mL (±36.6 U/mL) 
among control subjects and 22.4 U/mL (±52.3 U/mL) among 
cancer patients. Most women provided blood specimens on two or 
more occasions (range = 1  –  11 occasions) between 0 and 18 years 
before diagnosis among cancer patients (  Figure 1  ) and during a 
comparable time interval before the reference date among control 
subjects.                 
  Among control subjects, modest pairwise Pearson correlations 
were found between levels of spondin-2 and B7-H4 (  r   = .41,   P   = 
.003), DcR3 (  r   = .44,   P   < .001), and CA125 (  r   = .37,   P   = .002). 
Among cancer patients, the only correlation that reached statistical 
signiﬁ  cance at the   P     ≤   .008 level was between spondin-2 and DcR3 
(  r   = .59,   P   < .001) (    Supplementary     Table     1    , available online). 
  Available tumor characteristics indicate that 16 of the 34 cancer 
patients were diagnosed with serous carcinoma, including 15 
known to be at advanced stage (  Table 2  ). The other histologies 
observed included mucinous (n = 5), adenocarcinoma not other-
wise speciﬁ  ed (n = 4), and endometrioid (n = 3). Early-stage tumors 
were primarily mucinous. Of the 23 cancers with available tumor 
grade information, 13 (57%) were anaplastic, seven (30%) were 
poorly differentiated, and three (13%) were moderately 
differentiated.         
  Similar CA125 protein levels were observed between cancer 
patients and control subjects until approximately 3 years before 
diagnosis of ovarian cancer, at which point (by visual inspection), 
the mean marker level among cancer patients began to rise 
(  Figure 2  , A). A similar pattern, though less pronounced, was 
observed for HE4 protein levels and to a lesser extent, for meso-
thelin protein levels (  Figure 2  , B and C). Levels of B7-H4 and 
DcR3 in cancer patients and control subjects were indistinguish-
able throughout the study (  Figure 2  , D and E). Spondin-2 levels 
showed a slight increase over time among cancer patients result-
ing in a small separation during the ﬁ  nal year before diagnosis 
(  Figure 2  , F).         
  In descriptive analyses, the discriminatory power of the indi-
vidual markers, as assessed by ROC methods, was limited (with 
AUC statistics that ranged from 0.56 to 0.75) but showed in-
creasing accuracy with time approaching diagnosis (  Figure 3  , 
A  –  F). For CA125, the AUC statistics that were based on 68, 18, 
and 14 samples, respectively, were 0.57, 0.68, and 0.74 for the 
intervals of 4 or more years, 2  –  4 years, and less than 2 years before 
diagnosis. A ﬁ  ner division of the time axis gave a stronger gradient 
in AUC statistics, with an AUC of 0.89 for the ﬁ  nal year before 
diagnosis (    Supplementary     Figure     1  ,   A    , available online). ROC 
curves for HE4, mesothelin, B7-H4, DcR3, and spondin-2 provide 
a similar pattern of generally improving classiﬁ  cation as the time 
to diagnosis decreased (  Figure 3  , B  –  F and     Supplementary     Figure   
  1    , B  –  F, available online).         
  Lowess curves of mean levels over time before diagnosis of 
composite marker 1, deﬁ  ned for each observation on each woman 
as the sum of her standardized levels of CA125, HE4, and meso-
thelin, indicated that the level of this composite marker began to 
rise 4  –  5 years before diagnosis in cancer patients (  Figure 4  , A). 
Summing all six markers (ie, composite marker 2) did not alter this 
pattern substantially (  Figure 4  , B). Composite marker 3, deﬁ  ned 
for each observation on each woman as the maximum of her stan-
dardized biomarker levels of CA125, HE4, and mesothelin, and 
composite marker 4, similarly deﬁ  ned as the maximum of all six 
standardized levels at each time point, also indicated a change in 
the levels of these composite markers among cancer patients at 
approximately 3 years before diagnosis (  Figure 4  , C and D). The 
corresponding ROC curves and AUC statistics for composite 
markers 1  –  4 (  Figure 4  , E  –  H) indicated only small improvements 
in classiﬁ  cation performance over individual markers.         
  The above analyses use marker data in a retrospective fashion, 
evaluating their performance against a known time of diagnosis. In 
practice, however, a marker would be assessed and decisions made 
on the basis of a woman’s estimated probability of being diagnosed 
with cancer, conditional on currently available marker levels and 
other risk factors or symptoms, but without any information 
regarding time to diagnosis. 
  We used Cox regression models to assess the value of CA125, 
HE4, mesothelin, B7-H4, DcR3, and spondin-2 individually and 
in combinations (ie, composite makers 1  –  4) in this prospective 
setting. In the model evaluating CA125 alone, an elevation in 
CA125 level of 1 SD was associated with an increased risk 
of ovarian cancer (hazard ratio [HR] = 1.42, 95% conﬁ  dence 
interval = 1.18 to 1.70;   P   < .001) (  Table 3  ), implying that women 
in this population with a CA125 level of 53 U/mL would have an 
incidence rate that was approximately 1.4 times higher than that 
of comparable women with a CA125 level of 16 U/mL. In sepa-
rate models, HE4, mesothelin, and spondin-2 were associated 
with statistically signiﬁ   cantly elevated risks of ovarian cancer 
(with HRs ranging from 1.35 to 1.58) (  Table 3  ). Composite 
markers 1  –  4 were also associated with statistically signiﬁ  cantly 
increased risks of ovarian cancer; however, use of all six markers 
(ie, composite markers 2 and 4) did not provide stronger results 
than those that were based solely on CA125, HE4, and mesothe-
lin levels (composite markers 1 and 3).         
  Ovarian cancer is a heterogeneous disease, with serous his-
tology being the most prevalent and one of the most lethal sub-
types in postmenopausal women. Serous tumors are almost always 
detected at a late stage. Biomarkers that have shown promise for 
ovarian cancer have been chosen primarily for their ability to iden-
tify patients with late-stage serous disease. We hypothesized that 
any signal observed in the overall group might be stronger in a 
more homogeneous group that contained only serous tumors. We 
repeated the Cox regression models in the small subgroup of 
16 patients with serous ovarian cancer and found somewhat higher 
risks associated with all of the individual markers and composite 
markers, except for B7-H4 (  Table 3  ), although only the hazard 
ratios for CA125, HE4, or spondin-2 and the four composite 
markers  ’   risk reached statistical signiﬁ  cance. 
  To examine these markers jointly, we used a forward stepwise 
procedure to select the most predictive set of individual markers 
within the same general regression model. Only CA125 and meso-
thelin entered this model. In analyses limiting cancer patients to jnci.oxfordjournals.org    JNCI | Articles 31
  Table 1    .       Baseline characteristics of ovarian cancer patients and matched control subjects in Carotene and Retinol Efficacy Trial (CARET)   
    Characteristic Control subjects Cancer patients
  P    *      Total, No. (%) 70 (100.0) 34 (100.0)   
    Race, No. (%) 
         White 68 (97.1) 33 (97.1) .98 
         African American 2 (2.9) 1 (2.9)  
  Education level, No. (%) 
         High school or less 21 (30.0) 8 (23.5) .63 
         Some college 37 (52.9) 17 (50.0)  
         Postgraduate education 8 (11.4) 7 (20.6)  
         Missing 4 (5.7) 2 (5.9)  
  Smoking status, No. (%) 
         Former 25 (35.7) 8 (23.5) .21 
         Current 45 (64.3) 26 (76.5)  
  CARET intervention arm, No. (%) 
         Active 42 (60.0) 16 (47.1) .21 
         Placebo 28 (40.0) 18 (52.9)  
  Personal history of cancer, No. (%) 
         Yes 8 (11.4) 8 (23.5) .23 
         No 61 (87.1) 26 (76.5)  
         Missing 1 (1.4) 0 (0)  
  Personal history of breast cancer, No. (%) 
         Yes 2 (2.9) 1 (2.9) .98 
         No 68 (97.1) 33 (97.1)  
  Personal history of cervix cancer, No. (%) 
         Yes 2 (2.9) 2 (5.9) .45 
         No 68 (97.1) 32 (94.1)  
  Personal history of uterus cancer, No. (%) 
         Yes 1 (1.4) 3 (8.8) .07 
         No 69 (98.6) 31 (91.2)  
  No. of children who survived to 21 y (%) 
         None 4 (5.7) 3 (8.8) .78 
         1  –  2 17 (24.3) 11 (32.4)  
         3  –  4 37 (52.9) 15 (44.1)  
           ≥  5 11 (15.7) 5 (14.7)  
         Missing 1 (1.4) 0 (0)  
  Family history of cancer, No. (%) 
         Yes 50 (71.4) 25 (73.5) .82 
         No 20 (28.6) 9 (26.5)  
  Family history of breast cancer, No. (%) 
         Yes 11 (15.7) 4 (11.8) .59 
         No 59 (84.3) 30 (88.2)  
  Family history of ovary cancer, No. (%) 
         Yes 1 (1.4) 2 (5.9) .20 
         No 69 (98.6) 32 (94.1)  
  Family history of uterus/cervix cancer, No. (%) 
         Yes 10 (14.3) 3 (8.8) .43 
         No 60 (85.7) 31 (91.2)  
  Self-report of problems of the female organs, No. (%) 
         Yes 28 (40.0) 14 (41.2) .91 
         No 42 (60.0) 20 (58.8)  
  Age at CARET enrollment, y (mean ± SD) 70 (59.0 ± 5.7) 34 (59.0 ± 5.6) .98 
  Height, inches (mean ± SD) 70 (63.9 ± 2.5) 34 (64.5 ± 1.9) .21 
  Weight, pounds (mean ± SD) 69 (153.5 ± 33.4) 34 (155.6 ± 30.8) .76 
  Body mass index, kg/m 
2   (mean ± SD) 69 (26.4 ± 5.0) 34 (26.3 ± 5.3) .95 
  Pack-years of smoking, No. (mean ± SD) 70 (43.0 ± 19.4) 34 (44.9 ± 18.7) .63 
  Standardized biomarker levels at baseline (mean ± SD) 
         CA125 69 (    0.01 ± 0.99) 34 (0.16 ± 1.22) .43 
         HE4 70 (0.00 ± 0.98) 34 (0.18 ± 1.14) .41 
         Mesothelin 70 (0.01 ± 1.00) 34 (0.18 ± 0.95) .42 
         B7-H4 70 (0.00 ± 1.01) 34 (    0.06 ± 0.91) .77 
         DcR3 70 (    0.01 ± 0.99) 34 (0.05 ± 0.66) .76 
         Spondin-2 70 (0.02 ± 0.99) 34 (0.39 ± 0.86) .07   
    *       P   values for categorical variables are from       2   tests and for continuous variables are from   t   tests. All statistical tests were two-sided. DcR3 = decoy receptor 3; 
HE4 = human epididymis protein 4.     32   Articles | JNCI  Vol. 102, Issue 1  |  January 6, 2010
those with serous tumors, only CA125 and HE4 were found to be 
predictive of ovarian cancer (  Table 3  ).   
    Discussion 
  In this nested case  –  control study of 34 patients with ovarian cancer 
and 70 matched control subjects, preclinical elevations in CA125, 
HE4, and mesothelin appeared to provide evidence of ovarian 
cancer as early as 3 years before clinical diagnosis, but the likely 
lead time associated with these markers is less than 1 year. Levels 
of B7-H4, spondin-2, and DcR3 did not rise appreciably before an 
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    Figure 1    .        Times of       blood collections and ovarian cancer diagnosis 
among women who developed ovarian cancer during the Carotene and 
Retinol Efﬁ  cacy Trial.   Open circles   = times of blood collections;   solid 
circles   = time of ovarian cancer diagnosis.         
  Table 2    .       Distribution of tumor characteristics  *     
    Histology (  ICD-02   histology code) Total
FIGO stage 
  IA IC IIC IIIA IIIB IIIC IVC Unknown 
  Total, No. (%)    †    34 (100) 3 (8.8) 3 (8.8) 1 (2.9) 1 (2.9) 1 (2.9) 18 (52.9) 1 (2.9) 6 (17.6)   
    Adenocarcinoma, NOS (8140) 4 (11.8) 0 0 1 0 0 2 1 0 
  Endometrioid carcinoma (8380) 3 (8.8) 0 1 0 0 0 2 0 0 
  Serous carcinoma (8441, 8460, 8461)    †   16  (47.1) 0 0 0 1 1 13 0 1 
  Mucinous carcinoma (8470, 8472, 8480)    †   5  (14.7) 3 2 0 0 0 0 0 0 
  Unknown 6 (17.6) 0 0 0 0 0 1 0 5   
    *     FIGO = International Federation of Gynecology and Obstetrics;   ICD-02   =   International Classification of Disease, version 2  ; NOS = not otherwise specified.   
      †       Values in parentheses are percentages of cancer patients.     
ovarian cancer diagnosis, even though levels of these three markers 
have previously been shown to be elevated at the time of clinical 
diagnosis (  45  ). Use of composite markers may improve early detec-
tion performance, but only marginally. Furthermore, the value of 
these three markers for predicting ovarian cancer in clinical 
decisions must be verified in independent studies. In prospective 
Cox model analyses, CA125 continued to be the biomarker most 
strongly predictive of ovarian cancer, with evidence that HE4 and 
mesothelin may also contribute to risk prediction. 
  This study is one of the ﬁ  rst to evaluate novel ovarian cancer 
markers in a large well-annotated repository from a prevention 
study. The study design efﬁ  ciently minimized the chance for bias 
related to differential sample collection, processing, and storage. 
To reduce other potential biases, all laboratory staff were blinded 
to all participant information throughout the study, and detailed 
design and analysis steps were taken to control for known sources 
of variation. 
  This study had several limitations. The sample size was small, and 
all women had a history of heavy smoking. Few women had blood 
collections during the past 2  –  3 years before diagnosis, and pathology 
information was not available for six cancer patients. Lack of differ-
ences between cancer patients and control subjects could arise if an 
analyte was prone to degradation during long-term storage. 
  Aspects of the analyses also limit the interpretation of results. 
Because women contributed biomarker levels at different times 
before diagnosis, the analyses examined marginal trends in bio-
marker concentrations over time and must be interpreted with 
caution. Inclusion of multiple observations per woman in esti-
mating ROC curves invalidates traditional variance calculations. 
Consequently, these analyses should be viewed as descriptive. The 
ROC and Cox model analyses in this study do not use the full in-
formation in these serial samples. More sophisticated approaches, 
such as the parametric empirical Bayes algorithm (  12  ), use the 
history of biomarker levels within a woman to improve sensitivity 
to change from their natural levels. Application of the parametric em  -
pirical Bayes algorithm to these data did not materially change the 
suggested lead time but did increase the test accuracy of CA125 
and mesothelin (    Supplementary     Figures     2      –      5    , available online), 
consistent with previous reports (  52  ,  53  ), and suggested somewhat 
stronger disease associations for mesothelin and HE4 in Cox 
models (data not shown). Finally, the subgroup of serous ovarian 
cancers had a small sample size. The stronger association between 
biomarker level and risk of ovarian cancer observed in this sub-
group supports our hypothesis that these markers may perform jnci.oxfordjournals.org    JNCI | Articles 33
better in this more homogeneous subset, but this result needs 
conﬁ  rmation in a much larger dataset. 
  What do these data say about the potential role of these markers 
for early detection and intervention? It is often stated that a positive 
predictive value of 10% is required because a deﬁ  nitive diagnosis 
requires surgery. From both the patient and an economic perspec-
tive, a higher level of accuracy is desirable. But, for a rare disease 
such as ovarian cancer with an annual incidence rate of roughly 40 
new diagnoses per 100    000 postmenopausal women, the accuracy 
required to achieve a positive predictive value of 10% approaches 
perfection for both sensitivity and speciﬁ  city (  Table 4        ).         
  The performance statistics for the biomarkers evaluated in this 
study do not meet these accuracy requirements, either as single or 
composite markers. Adequate discrimination may be achieved by 
use of multiple markers up to 1 year before diagnosis (   Supplementary   
  Figure     1    , available online), but reaching these performance targets 
with longer lead time remains a considerable challenge. 
  The 10% positive predictive value threshold refers to the re-
quirements of an entire screening program, however, which typi-
cally includes both biomarkers and an imaging modality, such as 
transvaginal sonography. There are two ongoing trials evaluating 
CA125 and transvaginal sonography. The       UK Collaborative Trial 
of Ovarian Cancer Screening requires both CA125 and transvagi-
nal sonography to be positive for surgical referral (  54  ): The 
Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial 
(PLCO) requires that one or the other is positive (  55  ). The PLCO 
trial showed that a positive test, deﬁ  ned as either an elevation in 
CA125 or an abnormal transvaginal sonography examination, 
produced a 5% positive predictive value but that a 10% positive 
predictive value may be practicably obtainable by requiring both 
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    Figure 2    .       Lowess curves of standardized marker levels by time before diagnosis or reference date. Standardized marker levels were rescaled to 
have a mean of 0 and a SD of 1 among control subjects.   A  ) CA125. One cancer patient and one control subject had standardized CA125 levels that 
were greater than 6 and so were excluded from the graph.   B  ) Human epididymis protein 4.   C  ) Mesothelin.   D  ) B7-H4.   E  ) Decoy receptor 3. 
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CA125 and transvaginal sonography criteria to be met. In this 
study, the absence of imaging data precludes the estimation of 
positive predictive value for a multimodal strategy. 
  Ultimately, the clinical utility of any ovarian cancer screening 
program will depend on its ability to reduce ovarian cancer  –  related 
mortality. The longitudinal behavior of CA125, HE4, and meso-
thelin indicates that blood from women with cancer may contain 
evidence of disease 3 years or more before clinical diagnosis, at 
least when most patients are diagnosed with advanced-stage 
disease. This time frame is consistent with the longer intervals that 
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have been reported in the few other studies in prediagnostic spec-
imens (  5  ,  56  ,  57  ). The lead time, which is deﬁ  ned as the interval 
from screen-detected cancer to clinical diagnosis in the absence 
of screening (  1  ), depends on many parameters, including the rela-
tive magnitude of the marker elevation over time, the screening 
frequency, the algorithm for deﬁ  ning a positive test, and the 
performance of any other screening modality used. Because the 
elevation of these markers is not detectable until within a year of 
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  Table 3    .       Associations between biomarkers and ovarian cancer risk  *     
   
All ovarian cancer (n = 34) Serous ovarian cancers (n = 16) 
  HR (95% CI)    †     P  HR (95% CI)    ‡     P     
    Individual biomarker analyses 
    CA125 1.42 (1.18 to 1.70) <.001 1.62 (1.24 to 2.12) <.001 
    HE4 1.45 (1.08 to 1.96) .015 1.59 (1.09 to 2.34) .017 
    Mesothelin 1.35 (1.01 to 1.80) .045 1.46 (0.97 to 2.21) .072 
    B7-H4 1.20 (0.86 to 1.67) .284 1.02 (0.61 to 1.69) .947 
    DcR3 1.09 (0.71 to 1.68) .696 1.22 (0.69 to 2.15) .487 
    Spondin-2 1.58 (1.11 to 2.23) .010 1.74 (1.08 to 2.80) .022 
    CM1 1.34 (1.18 to 1.53) <.001 1.42 (1.19 to 1.70) <.001 
    CM2 1.18 (1.09 to 1.29) <.001 1.23 (1.09 to 1.39) <.001 
    CM3 1.44 (1.19 to 1.74) <.001 1.69 (1.29 to 2.21) <.001 
    CM4 1.44 (1.16 to 1.79) .001 1.62 (1.19 to 2.21) .002 
  Stepwise multivariable analyses  §   
    CA125 1.48 (1.23 to 1.78) <.001 1.60 (1.22 to 2.09) <.001 
    HE4     1.52 (1.05 to 2.19) .026 
    Mesothelin 1.46 (1.07 to 1.98) .016      
    *     Associations were obtained by use of standardized time-dependent biomarker levels that were modeled individually and in stepwise multivariable Cox models. 
CI = confidence interval; CM1 = composite marker 1, defined as the sum of CA125, HE4, and mesothelin; CM2 = sum of CA125, HE4, mesothelin, B7-H4, 
DcR3, and spondin-2; CM3 = maximum of CA125, HE4, and mesothelin; CM4 = maximum of CA125, HE4, mesothelin, B7-H4, DcR3, and spondin-2; 
DcR3 = decoy receptor 3; HE4 = human epididymis protein 4; HR = hazard ratio.   
      †       Cox regression model adjusted for age at Carotene and Retinol Efficacy Trial (CARET) enrollment, race (white vs African American), and history of female relatives 
with breast or ovarian cancer (yes/no).   P   values based on Wald statistics. All statistical tests were two-sided.   
      ‡       Cox regression model adjusted for age at CARET enrollment and female relatives with breast or ovarian cancer.   
    §     Cox regression models used a forward selection procedure at 5% level with adjustments as above.     
  Figure 4    .       Lowess curves of standardized marker levels by time before 
diagnosis or reference date (  A    –    D  ) and corresponding receiver oper-
ating characteristic curves by time before diagnosis (  E    –    H  ) for com-
posite markers.   A   and   E  ) Composite marker 1 (deﬁ   ned for each 
observation on each woman as the sum of her CA125, human epidid-
ymis protein 4 [HE4], and mesothelin levels).   B   and   F  ) Composite 
marker 2 (similarly deﬁ  ned as the sum of levels of all markers). One 
cancer patient had a value for composite marker 2 that was greater 
than 12 and so was excluded from the graph in (  B  ).   C   and   G  ) 
Composite marker 3 (deﬁ  ned for each observation on each woman as 
the maximum of her standardized CA125, HE4, or mesothelin levels). 
  D   and   H  ) Composite marker 4 (similarly deﬁ  ned as the maximum of 
all marker levels). One cancer patient and one control subject had 
values for composite markers 3 and 4 that were greater than 6 and so 
were excluded from the graphs in (  C  ) and (  D  ). Dx = diagnosis; AUC = 
area under the curve.       36   Articles | JNCI  Vol. 102, Issue 1  |  January 6, 2010
diagnosis, one cannot expect these markers to routinely detect 
cancer more than a year earlier than it would be diagnosed clini-
cally, regardless of the screening interval. It is not known whether 
a 1-year lead time is adequate to impact mortality. 
  Although these markers are not accurate enough to prompt 
early intervention in existing screening protocols, the multivari-
able regression analyses identiﬁ  ed modest but statistically signif-
icant increases in risk associated with CA125, HE4, and 
mesothelin, which are consistent with many of the established 
epidemiological risk factors for ovarian cancer. For example, the 
risk of ovarian cancer associated with an elevation of 1 or 2 SDs 
in CA125 levels is as strong as that for most menstrual and repro-
ductive risk factors (  58  ) and similar in magnitude with several of 
the factors used in the Gail model for estimating breast cancer 
risk (  59  ). As such, these markers should be considered, in con-
junction with other epidemiological risk factors when developing 
ovarian cancer risk models. 
  To have the greatest impact, new efforts should focus on iden-
tifying markers that extend lead time rather than those that simply 
add sensitivity near the time of clinical diagnosis. The length of 
the preclinical period observed in this study provides some hope 
that lead times approaching 3 years or more could be obtained if 
the right circulating proteins are identiﬁ  ed. The approach to dis-
covering these proteins is less clear. Other existing candidates 
could be evaluated in preclinical specimens, as we did in this study. 
The markers that we selected for evaluation had the highest sensi-
tivity and speciﬁ  city in clinically advanced samples, yet half of 
them were not predictive of disease prospectively. Thus, one 
should not expect many of the other existing markers to substan-
tially improve performance. Use of proteomics technologies to 
discover markers in prediagnostic samples is still a largely untested 
approach. Although appealing in principle, even the most sensitive 
technologies can rarely measure plasma proteins at concentrations 
that are lower than 10 ng/mL (  60  ,  61  ), which may be far above the 
concentrations that exist in early preclinical ovarian cancer 
  Table 4    .       Examples of test accuracy required to achieve a 10% 
positive predictive value in populations with incidence rates of 
ovarian cancer ranging from that of the general US population of 
postmenopausal women to a population with a 10-fold increase 
in risk   
    Incidence per 100    000 
persons per y Sensitivity, % Specificity, %   
    40 100 99.6 
  80 99.7 
  60 99.8 
  80 100 99.3 
  80 99.4 
  60 99.6 
  160 100 98.6 
  80 98.8 
  60 99.1 
  200 100 98.2 
  80 98.6 
  60 98.9 
  400 100 96.4 
  80 97.1 
  60 97.8   
samples (  62  ). Moreover, the results of the PLCO trial, which 
showed that CA125 alone performed better than transvaginal 
sonography alone (  55  ), suggest that improvements in imaging are 
needed and may have considerable impact on achieving early 
detection goals. Additional studies describing these and other novel 
marker levels over the prediagnostic interval would help to improve 
the precision of these classiﬁ  cation estimates over time, to develop 
optimal composite markers and screening algorithms, and to 
develop risk models that incorporate biomarker information.   
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